# A Study of MHB009C in Patients With Advanced Solid Tumors

> **NCT07326488** · PHASE1,PHASE2 · RECRUITING · sponsor: **Minghui Pharmaceutical (Hangzhou) Ltd** · enrollment: 200 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumor

## Interventions

- **DRUG:** MHB009C for Injection

## Key facts

- **NCT ID:** NCT07326488
- **Lead sponsor:** Minghui Pharmaceutical (Hangzhou) Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2028-02
- **Final completion:** 2029-03
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07326488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07326488, "A Study of MHB009C in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07326488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*